Pattern Scanning Laser Trabeculoplasty Program Obtains FDA Clearance

Source: Topcon Medical Systems

Monday, December 04, 2017 | FDA Approval/Clearance , Product Releases , Topcon Medical Systems


Topcon Medical Systems announced that its PASCAL Laser has received FDA clearance (K171488) to offer Pattern Scanning Laser Trabeculoplasty (PSLT) for the reduction of IOP associated with glaucoma.

Pattern Scanning Laser Trabeculoplasty, which is an optional software that can be installed on PASCAL Streamline lasers, is an advanced tissue-sparing laser treatment for reducing intraocular pressure in open angle glaucoma. PSLT provides a rapid, precise, and minimally traumatic computer-guided treatment that applies a sequence of patterns onto the trabecular meshwork. Automated rotation of consecutive patterns ensures that treatment steps are precisely placed without overlap or excessive gaps. Clinical studies of PSLT show an average IOP reduction of 24% in 6 months.

“By providing a computer-guided approach using PSLT, the PASCAL system makes laser treatment of the anterior segment, a sometimes challenging task, very manageable,” Dr. Sandra Belalcazar-Rey, Universidad del Rosario, Bogotá, Colombia. Dr. Kaweh Mansouri, Montchoisi Clinic, Switzerland, said in a company news releaes. "My experience with PSLT indicates that compared to traditional laser glaucoma treatments, such as SLT, PSLT offers comparable safety and efficacy with less patient discomfort."

“The availability of PSLT, offers now a clinically-proven glaucoma treatment technology to ophthalmologists in the United States,” said Robert Gibson, Vice President, Eye Care Global Marketing, Topcon Corporation. “Globally, we’ve seen success with the Streamline’ PSLT application and believe glaucoma specialists and comprehensive ophthalmologists in the United States will find this technology a useful addition to their treatment armamentarium.”

To learn more about the PSLT technique, visit http://pascalvision.com/science/#pslt

 


Comments

You must be logged in to leave a comment.